Open AccessSafety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer
Author(s) -
Karen A. Autio,
Robert Dreicer,
Justine Anderson,
Jorge A. García,
Ajjai Alva,
Lowell L. Hart,
Matthew I. Milowsky,
Edwin M. Posadas,
Charles J. Ryan,
Ryon P. Graf,
Ryan Dittamore,
Nicole A. Schreiber,
Jason M. Summa,
Hagop Youssoufian,
Michael J. Morris,
Howard I. Scher
Publication year - 2018
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2018.2168
Subject(s) - medicine , prostate cancer , enzalutamide , docetaxel , oncology , glutamate carboxypeptidase ii , prostate specific antigen , abiraterone acetate , cancer , urology , androgen deprivation therapy , androgen receptor
Preferential delivery of docetaxel to tumors by prostate-specific membrane antigen (PSMA)-targeted nanoparticles is clinically effective, and the selective reduction of PSMA-positive circulating tumor cells (CTCs) after treatment has implications for patient selection and disease monitoring.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom